Novo Nordisk has raised the number of staff it will shed this year in order to invest more in developing new drugs and supporting its most important products.
AstraZeneca will keep manufacturing investments in Britain on hold if the UK’s negotiations with Brussels fail to provide clarity on future trading relations, according to press reports.
Novo Nordisk has poached a top executive from AstraZeneca, tasking Ludovic Helfgott to lead development of its haemophilia and human growth hormone franchises.
Novo Nordisk is to launch “connected” insulin pens, responding for demands from patients for devices able to communicate with glucose monitoring systems and glucose meters.